- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 26 March 2025
Submitting member has a registered interest.
-
Current Status:
Answered by Jenni Minto on 22 April 2025
To ask the Scottish Government for what reason pharmacists working in communities reportedly do not have full access to clinical records for people in their care.
Answer
Community pharmacists currently have access to the Emergency Care Summary (ECS) which provides information on recent acute and repeat prescriptions and allergies and the Key Information Summary (KIS) where available, which provides information about a person’s health issues, a carer’s name and contact details, preferences on how a person would like to be cared for, the treatment they would like and where they would like to be cared for. In addition, several health boards are providing community pharmacists access to their clinical portal which provides additional clinical information.
There are several barriers that currently make full access to clinical records difficult including the interoperability of the different IT systems used across the NHS and providing assurances on data protection and information governance requirements.
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Monday, 24 March 2025
Submitting member has a registered interest.
-
Current Status:
Answered by Jenni Minto on 17 April 2025
To ask the Scottish Government what assessment it has made of the impact of the delay in implementing the Fracture Liaison Service audit on the ability to (a) evaluate gaps in osteoporosis care and (b) prevent avoidable fractures.
Answer
The Public Health Scotland (PHS) scoping exercise of Fracture Liaison Services (FLS) across NHS Boards, and subsequent business case, identified a need for a Scotland-wide FLS audit. Scottish Government acted on these findings and commissioned PHS to implement a national FLS audit.
The audit will create high-quality, standardised data and consistency across NHS Boards in order to identify and evaluate gaps in osteoporosis care, preventable harm to drive improvements, support clinical decision-making and reduce health inequalities.
Whilst there was an initial delay regarding recruitment, this has now been completed and progress now continues at pace. We do not expect the initial set up delays to impact on the overall delivery and outcomes of the FLS audit.
I refer the member to the answers to questions S6W-35534 on 21 March 2025 and S6W-36002 on 1 April 2025
All answers to written Parliamentary Questions are available on the Parliament’s website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 16 April 2025
-
Current Status:
Taken in the Chamber on 24 April 2025
To ask the Scottish Government whether it will provide an update on what support is available to teachers who experience physical violence or verbal abuse in schools.
Answer
Taken in the Chamber on 24 April 2025
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 19 March 2025
-
Current Status:
Answered by Natalie Don-Innes on 1 April 2025
To ask the Scottish Government what its response is to reports of some teachers requesting self-defence classes due to the prevalence of violence in schools.
Answer
It is the Government’s understanding that Freedom of Information requests recently released by Scotland’s Councils found that only two teachers across Scotland have made this request, whilst fifteen other Councils that responded said no requests have been made.
Our approach is focused on creating safe and nurturing schools, prioritising prevention and de-escalation of distressed behaviour.
Teachers and pupil support staff should be supported through their school’s relationships and behaviour policy. Arrangements for de-escalation and support should be provided to them where situations do escalate.
This is a view shared by some of our teaching unions, including NASUWT and the SSTA.
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 26 February 2025
Submitting member has a registered interest.
-
Current Status:
Answered by Jenni Minto on 11 March 2025
To ask the Scottish Government how many people in Scotland have (a) transfusion dependent thalassaemia and (b) sickle cell disease, also broken down by how many might be eligible for treatment with exagamglogene autotemcel, a gene-edited therapy manufactured in Scotland, if this was made available.
Answer
The Scottish Government does not hold data centrally on the numbers of people with transfusion-dependent thalassaemia or sickle cell disease.
The question of how many might be eligible for exagamglogene autotemcel treatment, if it were available, would be a matter for individual clinicians following all guidance on eligibility and any required testing to ascertain this.
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 26 February 2025
Submitting member has a registered interest.
-
Current Status:
Answered by Jenni Minto on 11 March 2025
To ask the Scottish Government, following the treatment, exagamglogene autotemcel, which is a gene-edited therapy manufactured in Scotland, being approved for use in England to treat (a) transfusion dependent thalassaemia and (b) sickle cell disease, what engagement it is having with the NHS and suppliers toward making this available in Scotland, also broken down by what date it will be made available to people eligible for it, if approved.
Answer
The Scottish Medicines Consortium (SMC) has received a submission through the Ultra-Orphan Pathway from the marketing authorisation holder, Vertex Pharmaceuticals, for exagamglogene autotemcel (Casgevy®) for the treatment of transfusion-dependent ß-thalassaemia in patients 12 years of age and older. A decision on whether Casgevy® is accepted on to the Ultra-Orphan Pathway for this indication will be published on the SMC website in due course.
The SMC has not yet received a submission from Vertex Pharmaceuticals for Casgevy® for the treatment of sickle cell disease (SCD). I refer the member to the answer to question S6W-34796 on 25 February 2025. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers.
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 05 March 2025
-
Current Status:
Taken in the Chamber on 13 March 2025
To ask the Scottish Government whether it will provide an update on the progress with the cladding remediation programme.
Answer
Taken in the Chamber on 13 March 2025
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 29 January 2025
-
Current Status:
Taken in the Chamber on 5 February 2025
To ask the Scottish Government what it is doing to support and grow the night-time economy in Glasgow.
Answer
Taken in the Chamber on 5 February 2025
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Wednesday, 22 January 2025
-
Current Status:
Taken in the Chamber on 29 January 2025
To ask the Scottish Government whether it will provide an update on the replacement of HMP Barlinnie, including in relation to the delivery date and cost.
Answer
Taken in the Chamber on 29 January 2025
- Asked by: Sandesh Gulhane, MSP for Glasgow, Scottish Conservative and Unionist Party
-
Date lodged: Thursday, 12 December 2024
Submitting member has a registered interest.
-
Current Status:
Answered by Jenni Minto on 6 January 2025
To ask the Scottish Government for which conditions policy will be developed as a result of the additional funding for long-term conditions outlined in its draft Budget 2025-26.
Answer
In addition to funding to support the expansion of access to diabetes technology already announced in the financial year 2024-2025, the draft Budget for 2025-2026 contains funding to support continued policy development for long term conditions including diabetes, respiratory conditions, chronic pain, neurological conditions, heart disease and out-of-hospital cardiac arrest.